KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Current Liabilities (2017 - 2025)

Historic Total Current Liabilities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $862.1 million.

  • Amneal Pharmaceuticals' Total Current Liabilities fell 2128.39% to $862.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $862.1 million, marking a year-over-year decrease of 2128.39%. This contributed to the annual value of $1.1 billion for FY2024, which is 3344.88% up from last year.
  • Amneal Pharmaceuticals' Total Current Liabilities amounted to $862.1 million in Q3 2025, which was down 2128.39% from $1.1 billion recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Total Current Liabilities high stood at $1.1 billion for Q4 2024, and its period low was $602.0 million during Q1 2022.
  • Moreover, its 5-year median value for Total Current Liabilities was $818.0 million (2022), whereas its average is $848.8 million.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Total Current Liabilities plummeted by 3401.7% in 2021 and then surged by 4758.81% in 2022.
  • Amneal Pharmaceuticals' Total Current Liabilities (Quarter) stood at $677.2 million in 2021, then grew by 11.16% to $752.8 million in 2022, then increased by 12.46% to $846.6 million in 2023, then soared by 33.45% to $1.1 billion in 2024, then dropped by 23.69% to $862.1 million in 2025.
  • Its Total Current Liabilities was $862.1 million in Q3 2025, compared to $1.1 billion in Q2 2025 and $1.1 billion in Q1 2025.